Abstract mTOR (mammalian target of rapamycin) has come a long way since its humble
beginnings as a kinase of unknown function. As part of the mTORC1 and mTORC2 …

The tumour-suppressor phosphatase with tensin homology (PTEN) is the most important
negative regulator of the cell-survival signalling pathway initiated by phosphatidylinositol 3 …

Mammalian target of rapamycin (mTOR) is a kinase that functions as a master switch
between catabolic and anabolic metabolism and as such is a target for the design of …

Inhibitors of the kinase mammalian target of rapamycin (mTOR) have shown sporadic
activity in cancer trials, leading to confusion about the appropriate clinical setting for their …

Proteins regulating the mammalian target of rapamycin (mTOR), as well as some of the
targets of the mTOR kinase, are overexpressed or mutated in cancer. Rapamycin, the …

Standard cytotoxic treatments for neuroendocrine tumours have been associated with
limited activity and remarkable toxicity. A phase II study was designed to evaluate the …

The discovery of a relationship for the VHL tumor suppressor gene, hypoxia inducible factor-
1 alpha, and vascular endothelial growth factor in the growth of clear-cell renal cell …

Abstract Purpose: Everolimus (RAD001, Novartis), an oral derivative of rapamycin, inhibits
the mammalian target of rapamycin (mTOR), which regulates many aspects of cell growth …

The receptor for epidermal growth factor (EGFR) is overexpressed in many cancers. One
important signaling pathway regulated by EGFR is the phosphatidylinositol 3′-kinase …

The mammalian target of rapamycin (mTOR), a protein kinase of the phosphatidylinositol 3-
kinase (PI3K)/Akt signaling pathway, has a central role in controlling malignant cellular …